Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck CancerBusiness Wire • 12/04/23
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell CarcinomaBusiness Wire • 12/04/23
Exelixis (EXEL) Up 8.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/01/23
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023Business Wire • 11/21/23
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023Business Wire • 11/10/23
Compared to Estimates, Exelixis (EXEL) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/02/23
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateBusiness Wire • 11/01/23
Strength Seen in Exelixis (EXEL): Can Its 5.6% Jump Turn into More Strength?Zacks Investment Research • 10/27/23
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 10/25/23
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023Business Wire • 10/22/23
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023Business Wire • 10/18/23